|
Winship Cancer Institute Cancer Center Support Grant
|
2P30CA138292-09
|
$2,524,399
|
$1,262,200
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S1
|
$59,999
|
$30,000
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S2
|
$102,081
|
$51,041
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Using donor pDC to optimize GvHD and GvL in allogeneic stem cell transplantation
|
5R01CA188523-04
|
$323,700
|
$323,700
|
WALLER, EDMUND
|
EMORY UNIVERSITY
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S3
|
$6,166,044
|
$184,981
|
FEARON, ERIC
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S4
|
$50,000
|
$1,500
|
FEARON, ERIC
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S5
|
$30,973
|
$929
|
FEARON, ERIC
|
UNIVERSITY OF MICHIGAN
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$272,402
|
$108,961
|
Fowler, Daniel
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Transplant Outcomes in Aplastic Anemia
|
ZIA CP010190-10508
|
$64,370
|
$64,370
|
Gadalla, Shahinaz
|
DCEG (NCI)
|
|
Translating Novel Drug-Targetable Biomarkers to Treat Graft versus Host Disease
|
5R01CA168814-05
|
$69,085
|
$69,085
|
PACZESNY, SOPHIE
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-33
|
$570,788
|
$142,697
|
DAVIDSON, NANCY
|
UNIVERSITY OF WASHINGTON
|
|
The Tisch Cancer Institute - Cancer Center Support Grant
|
5P30CA196521-03
|
$2,373,000
|
$118,650
|
BURAKOFF, STEVEN
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
The Role of Trisomy 21 in Hematopoiesis and Leukemogenesis
|
5F31CA196231-03
|
$30,564
|
$15,282
|
LIGGETT, LUTHER
|
UNIVERSITY OF COLORADO DENVER
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-05
|
$327,850
|
$163,925
|
CHEN, JIANJUN
|
UNIVERSITY OF CINCINNATI
|
|
The impact of aging-associated chronic inflammation on the selection for oncogenic driver mutations in hematopoietic stem cells
|
5F30CA210383-02
|
$31,389
|
$15,695
|
HIGA, KELLY
|
UNIVERSITY OF COLORADO DENVER
|
|
The Genetics of Post-Transplant Relapse in Myeloid Malignancy
|
5R01CA175008-05
|
$365,200
|
$365,200
|
RADICH, JERALD
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Th1-Th2 and Tc1-Tc2 T Cell Subsets in Transplantation Therapy
|
ZIA SC 010288
|
$544,803
|
$272,402
|
Fowler, Daniel
|
CCR (NCI)
|
|
Targeting novel DAMP mediated signaling pathways to mitigate GVHD
|
1R01CA217156-01A1
|
$426,640
|
$426,640
|
REDDY, PAVAN
|
UNIVERSITY OF MICHIGAN
|
|
Targeting Leukemia with Memory CD8+ T cells Transduced to Express High-Affinity W
|
5K08CA169485-05
|
$171,372
|
$171,372
|
CHAPUIS, AUDE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeting Granzyme B to Separate GVH from GVL Responses
|
5R01CA184728-03
|
$401,456
|
$401,456
|
CAO, XUEFANG
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Targeting Cdc42 for bone marrow transplant therapies
|
5R01CA193350-03
|
$356,850
|
$356,850
|
ZHENG, YI
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeting Beta-Adrenergic Signaling to Control GVH and GVL Responses
|
5R21CA202358-02
|
$189,334
|
$189,334
|
CAO, XUEFANG
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-09
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML
|
5K01CA188151-03
|
$169,020
|
$169,020
|
OROZCO, JOHNNIE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
T cell receptor proximal signaling
|
ZIA BC 011715
|
$279,574
|
$139,787
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
T cell Development and Regeneration
|
ZIA BC 011633
|
$1,082,718
|
$1,082,718
|
Bhandoola, Avinash
|
CCR (NCI)
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$380,715
|
$285,536
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-04
|
$312,304
|
$312,304
|
ZAIA, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stanford Cancer Institute
|
5P30CA124435-10
|
$3,338,488
|
$133,540
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
SPORE in Myeloid Malignancies
|
1P50CA206963-01A1
|
$2,185,000
|
$131,100
|
EBERT, BENJAMIN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-40S1
|
$131,625
|
$6,581
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-40S2
|
$116,944
|
$5,847
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
5P30CA016056-40
|
$4,052,483
|
$202,624
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Role of noncoding RNA in Regulating GVHD
|
5R01CA173878-05
|
$322,663
|
$322,663
|
REDDY, PAVAN
|
UNIVERSITY OF MICHIGAN
|
|
Role of ErbB receptor signaling in regulating normal and leukemic stem cell fate
|
5K08CA184552-04
|
$127,865
|
$38,360
|
DOAN, PHUONG
|
DUKE UNIVERSITY
|
|
Reconstitution of Regulatory T Cells After Stem Cell Transplantation
|
5R01CA183560-05
|
$500,000
|
$500,000
|
RITZ, JEROME
|
DANA-FARBER CANCER INST
|
|
Programming T Cell Fates for Therapeutic Use
|
ZIA BC 011480
|
$987,136
|
$246,784
|
Gattinoni, Luca
|
CCR (NCI)
|
|
Probiotics for Prevention of Acute Graft-vs-Host Disease in Children with Cancer
|
5R01CA201788-02
|
$208,949
|
$208,949
|
POLLOCK, BRAD
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Prevention of bone loss after pediatric hematopoietic cell transplantation
|
5R01CA181024-04
|
$1
|
$1
|
SARAFOGLOU, KYRIAKIE
|
UNIVERSITY OF MINNESOTA
|
|
Preclinical development and clinical monitoring of adoptive immune therapy
|
ZIC BC 011029
|
$420,830
|
$420,830
|
Hakim, Frances
|
CCR (NCI)
|
|
Pre-clinical Studies of Therapy for Myelodysplastic Syndrome
|
ZIA BC 010983
|
$380,330
|
$380,330
|
Aplan, Peter
|
CCR (NCI)
|
|
Postmortem Pathology
|
ZIC BC 010685
|
$699,211
|
$419,527
|
Kleiner, David
|
CCR (NCI)
|
|
Post-Transcriptional Regulation of Interleukin-7 Receptor Expression
|
ZIA BC 011214
|
$587,118
|
$88,068
|
Park, Jung-Hyun
|
CCR (NCI)
|
|
Pediatric Oncology Research Training Program
|
2T32CA009351-39
|
$272,307
|
$108,923
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Optimal Antiretroviral Therapy During Bone Marrow Transplant in HIV-1 Infection
|
5K23CA177321-04
|
$161,608
|
$161,608
|
DURAND, CHRISTINE
|
JOHNS HOPKINS UNIVERSITY
|
|
Novel Strategies for Cancer Immunotherapy in Stem Cell Transplant
|
5R01CA136934-09
|
$357,750
|
$357,750
|
YANG, YIPING
|
DUKE UNIVERSITY
|
|
Nonadherence: Undermining health outcomes in pediatric HSCT?
|
5R01CA157460-06
|
$269,433
|
$269,433
|
PAI, AHNA
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
NK cells, their receptors, transplantation and cancer therapy
|
5P01CA111412-12
|
$1,842,904
|
$1,529,610
|
MILLER, JEFFREY
|
UNIVERSITY OF MINNESOTA
|
|
Natural History Study of the Complications Associated with Allogeneic HCT
|
ZIA BC 011742
|
$269,487
|
$134,743
|
Gea-Banacloche, Juan
|
CCR (NCI)
|
Total relevant funding to Bone Marrow Transplantation for this search: $39,362,912
|